Type 2 diabetes

Treatment with dapagliflozin is associated with a significant reduction in the risk for heart failure worsening or cardiovascular death in people with heart failure and reduced ejection fraction regardless of whether or not they have diabetes, shows an exploratory analysis of DAPA-HF trial data.

Older adults with type 2 diabetes often receive diabetes medication adjustments at hospital discharge that may be of little or no benefit, study results suggest.

Adding liraglutide 3.0 mg to intensive behavioral therapy increases weight loss in overweight or obese people with insulin-treated type 2 diabetes, results of the phase 3 SCALE Insulin trial show.

More than half of people with coronary artery disease have impaired glucose tolerance, yet many are unaware of this or are undertreated despite knowledge of their condition, results of the EUROASPIRE V survey show.

The risk associated with a family history of type 2 diabetes is highest for people whose near relatives were diagnosed with the condition at a young age, show registry data.

Optimal glycemic control during the first years after a latent autoimmune diabetes of adulthood diagnosis could prevent people’s microvascular complication risk from equaling that seen in those with type 2 diabetes, shows an analysis of the UKPDS.

The benefits and harms of intensive glucose control in people with type 2 diabetes may depend on which form of haptoglobin they have, shows an analysis of the ACCORD trial.

Initiating insulin glargine 300 U/mL could help half of those patients whose type 2 diabetes is inadequately controlled with oral antidiabetic medication to achieve their personal glycemic target within a year, real-world data suggest.

Gaining weight after stopping smoking attenuates the cardiovascular disease benefits of quitting in people with type 2 diabetes, but does not appear to lessen its positive effect on mortality, shows research.

People with type 2 diabetes who are treated with sodium-glucose cotransporter 2 inhibitors are less likely to develop gout than those given glucagon-like peptide-1 receptor agonists, researchers report.

Patients with type 2 diabetes who are treated with SGLT2 inhibitors in routine clinical practice have a lower rate of kidney function decline and a reduced risk for adverse renal events compared with those given other glucose-lowering drugs, researchers report.

A large survey has uncovered a number of issues that particularly frustrate people with diabetes during their interactions with their healthcare providers.

People with type 2 diabetes and reduced kidney function in the absence of albuminuria have an increased risk for mortality and major adverse cardiovascular events, despite a low risk for end-stage renal disease, research shows.

Prediabetes has no effect on the short-term mortality risk of older adults, suggests an analysis of the Atherosclerosis Risk in Communities study.

Swedish research suggests that determining type 2 diabetes duration prior to bariatric surgery could help prioritize those patients most likely to achieve diabetes remission.

People who are trying to maintain weight loss with the help of electronic health records-based tracking tools do significantly better if they are given access to an online coach, shows a randomized trial.

Primary care physician Jay Shubrook shares his recommendations for diabetes management in a 72-year-old, multi-morbid patient.

Get more on: Older adults with type 2 diabetes | Diabetes comorbidities

People with obesity and type 2 diabetes who undergo gastric bypass surgery have higher rates of diabetes remission after 1 year than those undergoing sleeve gastrectomy, indicate findings from the Oseberg trial.

Sanjay Kalra discusses the World Diabetes Day theme, and evaluates the concerns and opportunities presented by “The Family and Diabetes”.

Adding the DPP-4 inhibitor sitagliptin to first-line metformin therapy may delay the need for exogenous insulin among people with type 2 diabetes, researchers report.